The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
Official Title: Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
Study ID: NCT04298892
Brief Summary: Exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may be included in this study, after obtaining informed consent
Detailed Description: Hematological malignancies account for approximately 9.5% of newly diagnosed cancers every year and their incidence shows an exponential rise after the age of 40. Since life expectancy is dramatically and continuously increasing worldwide, hematological diseases promise to become a substantial burden for the health care systems of the European society. The management of hematological malignancies is further complicated by the high level of disease heterogeneity in terms of pathogenic and molecular mechanisms. Due to the high level of heterogeneity in terms of cytogenetic, genetic, epigenetic, transcriptional, post-transcriptional and metabolic alterations, an accurate molecular classification of hematological diseases is needed to improve clinical outcomes and patients' management. This is an exploratory multicenter, non-interventional, translational, retrospective and prospective study. All patients with a diagnosis of hematologic disorder or malignancy for whom biological samples and clinical data are available may be included in this study, after obtaining informed consent. The primary objective is to improve our knowledge of the pathogenic mechanisms driving malignant disorders and transformation. The secondary objectives aim to improve diagnosis and stratification of onco-hematological patients and study drug response at preclinical level. After signing informed consent to the study, each patient will donate part of the samples (peripheral blood, bone marrow, biopsies) collected as per routine clinical practice for the management of their disease.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Irst Irccs, Meldola, FC, Italy
AOU Città della Salute e della scienza di Torino, Torino, TO, Italy
UO Hematology, Ospedale S. Maria delle Croci, Ravenna, , Italy
UO Hematology Ospedale Infermi, Rimini, , Italy
Ospedale Ca' Foncello Treviso, Treviso, , Italy
Name: Giovanni Martinelli, Prof
Affiliation: IRST IRCCS
Role: STUDY_DIRECTOR
Name: Alessandro Lucchesi, MD
Affiliation: IRST IRCCS
Role: PRINCIPAL_INVESTIGATOR